Roche to acquire Carmot Therapeutics for US$ 2.7 billion
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Both the India and GCC entities will be operated by separate dedicated management teams
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Subscribe To Our Newsletter & Stay Updated